GNI Group Ltd. (TSE:2160) Might Not Be As Mispriced As It Looks After Plunging 28%
Apr 11
Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedApr 15, 2025
DataAggregated Company Financials
Companies34
- 7D21.1%
- 3M-5.5%
- 1Y17.4%
- YTDn/a
All of the companies in the Biotech industry have been up over the last week, with the industry up 21%. In the last 12 months, the industry was up 17%. Looking forward, earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 15 Apr 2025 | JP¥988.7b | JP¥207.7b | -JP¥38,921,205,000.00 | 14.1x | -25.4x | 4.8x |
| Thu, 13 Mar 2025 | JP¥1.0t | JP¥207.4b | -JP¥38,725,942,000.00 | 16x | -26.1x | 4.9x |
| Sat, 08 Feb 2025 | JP¥1.0t | JP¥207.3b | -JP¥13,596,922,000.00 | 20.8x | -73.7x | 4.8x |
| Mon, 06 Jan 2025 | JP¥1.1t | JP¥207.3b | -JP¥13,531,081,000.00 | 22.3x | -80.1x | 5.2x |
| Wed, 04 Dec 2024 | JP¥1.1t | JP¥207.2b | -JP¥12,080,899,000.00 | 22.6x | -92.9x | 5.4x |
| Fri, 01 Nov 2024 | JP¥1.1t | JP¥214.3b | -JP¥3,941,502,000.00 | 22.9x | -279.5x | 5.1x |
| Sun, 29 Sep 2024 | JP¥1.1t | JP¥214.3b | -JP¥2,078,229,000.00 | 22x | -552.8x | 5.4x |
| Tue, 27 Aug 2024 | JP¥1.1t | JP¥210.1b | -JP¥580,439,000.00 | 16.6x | -1857.9x | 5.1x |
| Thu, 25 Jul 2024 | JP¥1.0t | JP¥187.7b | -JP¥15,871,901,000.00 | 94.7x | -66.1x | 5.6x |
| Sat, 22 Jun 2024 | JP¥897.7b | JP¥187.7b | -JP¥15,773,284,000.00 | 84.8x | -56.9x | 4.8x |
| Mon, 20 May 2024 | JP¥769.6b | JP¥195.9b | -JP¥13,410,545,000.00 | 93.1x | -57.4x | 3.9x |
| Wed, 17 Apr 2024 | JP¥738.7b | JP¥194.2b | -JP¥15,746,877,000.00 | 65.5x | -46.9x | 3.8x |
| Fri, 15 Mar 2024 | JP¥770.9b | JP¥194.2b | -JP¥18,497,703,000.00 | 58.4x | -41.7x | 4x |
| Sun, 11 Feb 2024 | JP¥747.3b | JP¥222.2b | -JP¥12,699,799,000.00 | 16.7x | -58.8x | 3.4x |
| Tue, 09 Jan 2024 | JP¥803.0b | JP¥222.3b | -JP¥12,668,455,000.00 | 17.4x | -63.4x | 3.6x |
| Thu, 07 Dec 2023 | JP¥792.3b | JP¥221.9b | -JP¥12,426,487,000.00 | 16.7x | -63.8x | 3.6x |
| Sat, 04 Nov 2023 | JP¥746.6b | JP¥223.0b | -JP¥14,350,085,000.00 | 19.3x | -52x | 3.3x |
| Mon, 02 Oct 2023 | JP¥847.8b | JP¥223.0b | -JP¥14,518,735,000.00 | 26.2x | -58.4x | 3.8x |
| Wed, 30 Aug 2023 | JP¥928.5b | JP¥225.1b | -JP¥19,814,131,000.00 | 50.4x | -46.9x | 4.1x |
| Fri, 28 Jul 2023 | JP¥908.4b | JP¥223.7b | -JP¥20,836,669,000.00 | 49.7x | -43.6x | 4.1x |
| Sun, 25 Jun 2023 | JP¥973.0b | JP¥223.2b | -JP¥20,139,670,000.00 | 64.6x | -48.3x | 4.4x |
| Tue, 23 May 2023 | JP¥916.3b | JP¥218.6b | -JP¥25,244,669,000.00 | 32.1x | -36.3x | 4.2x |
| Thu, 20 Apr 2023 | JP¥946.1b | JP¥218.1b | -JP¥20,115,522,000.00 | 21.5x | -47x | 4.3x |
| Sat, 18 Mar 2023 | JP¥935.3b | JP¥218.1b | -JP¥20,708,580,000.00 | 20.9x | -45.2x | 4.3x |
| Mon, 13 Feb 2023 | JP¥957.1b | JP¥200.4b | -JP¥25,348,917,000.00 | 38.1x | -37.8x | 4.8x |
| Wed, 11 Jan 2023 | JP¥902.6b | JP¥186.8b | -JP¥24,722,604,000.00 | 41x | -36.5x | 4.8x |
| Fri, 09 Dec 2022 | JP¥897.7b | JP¥186.6b | -JP¥26,666,433,000.00 | 44.6x | -33.7x | 4.8x |
| Sun, 06 Nov 2022 | JP¥813.4b | JP¥176.5b | -JP¥24,989,270,000.00 | 46.8x | -32.5x | 4.6x |
| Tue, 04 Oct 2022 | JP¥865.7b | JP¥176.5b | -JP¥24,974,270,000.00 | 43.3x | -34.7x | 4.9x |
| Thu, 01 Sep 2022 | JP¥955.2b | JP¥174.4b | -JP¥21,144,270,000.00 | 21.9x | -45.2x | 5.5x |
| Sat, 30 Jul 2022 | JP¥980.3b | JP¥171.3b | -JP¥16,251,673,000.00 | 21.2x | -60.3x | 5.7x |
| Mon, 27 Jun 2022 | JP¥879.1b | JP¥171.3b | -JP¥16,112,943,000.00 | 20.6x | -54.6x | 5.1x |
| Wed, 25 May 2022 | JP¥915.9b | JP¥169.3b | -JP¥13,349,721,000.00 | 11.3x | -68.6x | 5.4x |
| Fri, 22 Apr 2022 | JP¥1.0t | JP¥164.2b | -JP¥13,043,295,000.00 | 14.4x | -78.2x | 6.2x |
Price to Earnings Ratio
-78.2x
Current Industry PE
- Investors are relatively neutral on the Japanese Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 8.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Japanese Biotech compare with similar industries?
| JP Market | 8.73% | |
| Healthcare | 1.49% | |
| Biotech | 21.08% | |
| Biotech | 21.08% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4592 SanBio | JP¥2.14k | 29.5% +JP¥35.1b | 420.7% | PB87.4x | |
| 219A Heartseed | JP¥2.21k | 18.7% +JP¥7.8b | n/a | PS56.5x | |
| 2160 GNI Group | JP¥1.83k | 7.2% +JP¥6.1b | -29.0% | PE83.6x | |
| 4587 PeptiDream | JP¥1.88k | 2.2% +JP¥5.2b | 22.7% | PE16.3x | |
| 4593 Healios K.K | JP¥267.00 | 20.3% +JP¥4.6b | 81.6% | PS48.4x |